Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor. — From Psychiatric Times articles Read More
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT